Jill Walker

发表

Pharmacological disruption of hepatitis C NS5A protein intra- and intermolecular conformations.

R. Hamatake, R. Striker, W. Kazmierski, 2014, Journal of General Virology.

A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects

R. Hamatake, Z. Hong, M. Rodríguez-Torres, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.

R. Hamatake, Z. Hong, Shawn P. Williams, 2014, Journal of medicinal chemistry.

In Vitro Characterization of GSK2485852, a Novel Hepatitis C Virus Polymerase Inhibitor

R. Hamatake, Z. Hong, J. Vamathevan, 2013, Antimicrobial Agents and Chemotherapy.

Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism.

Ryan Lauchli, A. Mathis, John F. Miller, 2014, Journal of medicinal chemistry.

A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects

D. Wilfret, K. Adkison, A. Spaltenstein, 2014, Clinical pharmacology in drug development.

GSK2818713, a novel biphenylene scaffold-based Hepatitis C NS5A replication complex inhibitor with broad genotype coverage.

R. Hamatake, W. Kazmierski, R. Crosby, 2020, Journal of medicinal chemistry.

Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A

R. Hamatake, J. Vamathevan, W. Kazmierski, 2013, Antimicrobial Agents and Chemotherapy.

Running title: Preclinical characterization of GSK2336805

R. Hamatake, J. Vamathevan, W. Kazmierski, 2013 .

Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza

E. Kerwin, A. Madan, P. Yates, 2019, Open forum infectious diseases.

P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY

R. Hamatake, Z. Hong, R. Crosby, 2014 .

Pharmacologic disruption of Hepatitis C Non Structural 5 A ( NS 5 A ) intra and 1 intermolecular conformations 2 3

R. Hamatake, R. Striker, I. Ansari, 2013 .

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.

R. Hamatake, W. Kazmierski, R. Crosby, 2014, Journal of medicinal chemistry.